SLC1A5 and prostate cancer: Another report shows that the glutamine transporter ASCT2 (SLC1A5) is highly expressed in prostate cancer samples and chemical or shRNA-mediated inhibition of ASCT2 function in LNCaP and PC-3 prostate cancer cell lines inhibit glutamine uptake, cell cycle progression, mTORC1 pathway activation and cell growth.